

Randomisation Program

Call Freephone 0800 138 5451 to contact the RECOVERY team for URGENT problems using the Randomisation Program or for medical advice. All NON-URGENT queries should be emailed to recoverytrial@ndph.ox.ac.uk

Logged in as: RECOVERY Site

Section A: Baseline and Eligibility

Date and time of randomisation: 22 May 2021 14:00

**Treating clinician**  
A1. Name of treating clinician

**Patient details**  
A2. Patient surname   
Patient forename   
A3. NHS number   Tick if not available  
A4. What is the patient's date of birth?  /  /   
A5. What is the patient's sex?

**Inclusion criteria**  
A6. Has consent been taken in line with the protocol?  
If answer is No patient cannot be enrolled in the study   
A6.1 Has consent been given for the early phase assessment of dimethyl fumarate?  Yes   
A6.2 Has S/F<sub>94</sub> been measured according to the SOP?  Yes   
A7. Does the patient have proven or suspected SARS-CoV-2 infection?  
If answer is No patient cannot be enrolled in the study   
A8. Does the patient have any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial?   
A9. COVID-19 symptom onset date:  /  /   
A10. Date of hospitalisation:  /  /   
A11. Does the patient require oxygen?   
A12. Please select one of the following to describe the current level of ventilation support   
A12.1 Enter latest oxygen saturation measurement (%)   
A12.2 Enter latest CRP measurement since admission to hospital (mg/L)   Tick if not measured  
Enter 0 if below the limit of measurement  Tick if greater than limit of measurement  
A12.3 Enter latest creatinine measurement since admission to hospital   μmol/L  Tick if not measured  
A12.4 Enter latest D-dimer measurement since admission to hospital   ng/mL  Tick if not measured  
Enter 0 if below the limit of measurement  Tick if greater than limit of measurement  
A12.5 Has the patient received a COVID-19 vaccine?

**Does the patient have any CURRENT comorbidities or other medical problems or treatments?**  
A13.1 Diabetes   
A13.2 Heart disease   
A13.3 Chronic lung disease   
A13.4 Tuberculosis   
A13.5 HIV   
A13.6 Severe liver disease   
A13.7 Severe kidney impairment (eGFR <30 or on dialysis)   
A13.8 Known long QT syndrome   
A13.9 Current treatment with macrolide antibiotics which are to continue  
Macrolide antibiotics include clarithromycin, azithromycin and erythromycin   
A13.10 Antiplatelet therapy  
Includes aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole   
A13.12 Has received tocilizumab therapy during this admission

**Are the following treatments UNSUITABLE for the patient?**  
**If you answer Yes it means you think this patient should NOT receive this drug.**  
A14.3 Dimethyl fumarate  
Nil Dimethyl fumarate is NOT suitable if patient is pregnant or breastfeeding  No   
A14D.1 Baricitinib  
Nil Baricitinib is NOT suitable if patient (i) is pregnant; (ii) has eGFR <15 ml/min or is on dialysis/haemofiltration; (iii) has active TB; or (iv) has neutrophil count <0.5

**Are the following treatments available?**  
A15.3 Dimethyl fumarate  Yes   
A15D.1 Baricitinib

**Current medication**  
A16.1 Is the patient currently prescribed remdesivir?   
A16.2 Is the patient currently prescribed systemic corticosteroids (dexamethasone, prednisolone, hydrocortisone, methylprednisolone)?  
Please do not include topical or inhaled treatments   
A16.4 Is the patient currently on warfarin or a direct oral anticoagulant?  
Includes apixaban, rivaroxaban   
A16.5 What venous thromboembolism prophylaxis is the patient receiving?  
Standard = usual for hospitalised patients (not increased due to COVID-19); Higher dose = treatment dose or increased prophylaxis due to COVID-19

**A17.2 Early phase assessment of dimethyl fumarate: S/F<sub>94</sub> measurement**  
**This participant is eligible for this part of RECOVERY. Please enter their current S/F<sub>94</sub> (refer to SOP for instructions on measurement).**  
A17.2.1 Oxygen delivery mode   
A17.2.2 Inspired oxygen concentration (FIO<sub>2</sub>) (%)   
A17.2.3 High-flow nasal oxygen flow rate   
A17.2.4 Peak end-expiratory pressure (PEEP) (cm H<sub>2</sub>O)   
A17.2.5 Peripheral oxygen saturation (SpO<sub>2</sub>) (%)   
A17.2.6 Respiratory rate (breaths per minute)

**Please sign off this form once complete**  
Surname:   
Forename:   
Professional email: